GlobeNewswire: Flexion Therapeutics, Inc. Contains the last 10 of 283 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:21:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/10/11/2311713/0/en/Pacira-BioSciences-to-Acquire-Flexion-Therapeutics-Further-Expanding-Leadership-Position-in-Non-Opioid-Pain-Management.html?f=22&fvtc=4&fvtv=20985Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management2021-10-11T11:00:00Z<![CDATA[-- Adds highly complementary ZILRETTA® to Pacira commercial offering ---- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --]]>https://www.globenewswire.com/news-release/2021/10/01/2307364/0/en/Flexion-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2021-10-01T20:30:00Z<![CDATA[BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2021/09/08/2293839/0/en/Flexion-Therapeutics-to-Present-at-the-H-C-Wainwright-23rd-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference2021-09-08T20:30:00Z<![CDATA[BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.]]>https://www.globenewswire.com/news-release/2021/09/03/2291470/0/en/Flexion-Therapeutics-to-Present-at-the-Wells-Fargo-2021-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference2021-09-03T13:00:00Z<![CDATA[BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021.]]>https://www.globenewswire.com/news-release/2021/09/02/2290770/0/en/Flexion-Therapeutics-Announces-Inclusion-of-ZILRETTA-in-American-Academy-of-Orthopaedic-Surgeons-AAOS-Clinical-Practice-Guidelines-for-the-Management-of-Osteoarthritis-of-the-Knee.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee2021-09-02T11:30:00Z<![CDATA[BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.1]]>https://www.globenewswire.com/news-release/2021/08/25/2286225/0/en/Flexion-Therapeutics-Announces-Expansion-of-Phase-1b-Trial-Investigating-FX301-for-the-Management-of-Post-Operative-Pain.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain2021-08-25T11:30:00Z<![CDATA[BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function. The company’s decision to advance FX301 into the expansion cohort follows a review of safety data from the single ascending dose stage of the trial by an independent Safety Monitoring Committee. Subsequently, an internal review committee assessed safety, systemic exposure and efficacy data and made the decision to advance the program.]]>https://www.globenewswire.com/news-release/2021/08/09/2277483/0/en/Flexion-Therapeutics-Announces-Publication-of-Results-from-Phase-2-Pharmacokinetics-PK-and-Safety-Study-of-ZILRETTA-in-Shoulder-Osteoarthritis-OA.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)2021-08-09T20:30:00Z<![CDATA[BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Drugs in R&D. The study compared the plasma PK profile of ZILRETTA to immediate-release triamcinolone acetonide in crystalline suspension (TAcs) and assessed the safety and general tolerability of ZILRETTA in osteoarthritis (OA) of the shoulder.]]>https://www.globenewswire.com/news-release/2021/08/04/2274951/0/en/Flexion-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Business-Highlights.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights2021-08-04T20:01:00Z<![CDATA[BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.]]>https://www.globenewswire.com/news-release/2021/07/29/2271780/0/en/Flexion-Therapeutics-to-Report-Second-Quarter-2021-Financial-Results-on-August-4-2021.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 20212021-07-29T20:15:00Z<![CDATA[BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.]]>https://www.globenewswire.com/news-release/2021/07/12/2261512/0/en/Flexion-Therapeutics-Announces-Appointment-of-Utpal-Koppikar-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=20985Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors2021-07-12T20:30:00Z<![CDATA[BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit committee.]]>